Determination of Possible Biomarkers for Predicting Well-Differentiated Thyroid Cancer Recurrence by Different Ensemble Machine Learning Methods

Yıl 2024, Cilt: 10 Sayı: 3, 255 - 265, 31.08.2024

Şeyma Yaşar

https://doi.org/10.19127/mbsjohs.1498383

Öz

Objective: Well-differentiated thyroid cancer (WDTC) is the most common thyroid malignancy and although it is curable, the risk of recurrence is high. In this study, classification algorithms based on clinicopathologic features of WDTC patients were used to determine the possible of recurrence in WDTC and to evaluate potential predictive factors, and possible biomarkers based on the optimal model were identified.
Method: In this study, open access data on 383 patients with WDTC, 108 with recurrence and 275 without recurrence, were used. In order to predict recurrence in WDTC patients, features were selected using recursive feature elimination variable selection method among features and classification was performed with two ensemble learning methods (Random Forest, Adaboost).
Results: Two different ensemble learning models used to classify recurrence in WDTC were Random Forest with an accuracy of 0.957, sensitivity of 0.889, specificity of 0.978, positive predictive value of 0.923, negative predictive value of 0.967, Matthews correlation coefficient of 0.878, G-mean of 0.945, F1-score of 0.906, and accuracy of 0.940, sensitivity of 0.889, specificity of 0.955, positive predictive value of 0.857, negative predictive value of 0.966, Matthews correlation coefficient of 0.833, G-mean of 0.910, F1-score of 0.873.
Conclusion: According to variable importance based on the Random Forest, the 5 possible clinical biomarkers for predicting WDTC recurrence are Response, Risk, Node, Tumor, and age. In the light of these findings, patient management and treatment planning can be organized.

Anahtar Kelimeler

Well-Differentiated Thyroid Cancer, Recurrence, Random Forest, Adaboost

Etik Beyan

This study was approved by the Inonu University Non-invasive Clinical Research Ethics Committee (decision no: 2024/5931).

Kaynakça

• Adaş G, Adaş M, Özülker F, Akçakaya A. Thyroid cancers. Okmeydanı Tıp J. 2012;28: 26-34.
• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. Ca Cancer J Clin 2023;73:17-48.
• Vaish R, Mahajan A, Sable N, Dusane R, Deshmukh A, Bal M, D’cruz AK. Role of computed tomography in the evaluation of regional metastasis in well-differentiated thyroid cancer. Frontiers in Radiology 2023;3: 1243000.
• Chen DW, Lang BH, McLeod DS, Newbold K, Haymart MR. Thyroid cancer. The Lancet 2023;401:1531-1544.
• Boina R, Ganage D, Chincholkar YD, Wagh S, Shah DU, Chinthamu N, et al. Enhancing Intelligence Diagnostic Accuracy Based on Machine Learning Disease Classification. IJISAE (2023);11:765-774. 6. Mienye ID, Sun Y, Wang Z. An improved ensemble learning approach for the prediction of heart disease risk. IMU 2020;20:100402. 7. Yu L, Wang S, Lai KK. Credit risk assessment with a multistage neural network ensemble learning approach. Expert Syst. Appl. 2008;34:1434-1444.
• Borzooei S, Briganti G, Golparian M, Lechien JR, Tarokhian A. Machine learning for risk stratification of thyroid cancer patients: a 15-year cohort study. Eur Arch Otorhinolaryngol 2024;281:2095-2104.
• Misra P, Yadav AS. Improving the classification accuracy using recursive feature elimination with cross-validation. Int. J. Emerg. Technol, 2020;11:659-665.
• Rigatti SJ. Random forest. J Insur Med 2017;47:31-39.
• Freund Y, Schapire RE. A decision-theoretic generalization of on-line learning and an application to boosting. JCSS 1997;55:119-139.
• Bulut F. Determining Heart Attack Risk Ration Through AdaBoost/AdaBoost ile Kalp Krizi Risk Tespiti. CBUJOS 2016;12:459-472.
• George D, Mallery P. IBM SPSS statistics 26 step by step: A simple guide and reference. Routledge, 2019.
• Alfaro E, Gamez M, Garcia N. Adabag: An R package for classification with boosting and bagging. Journal of Statistical Software 2013; 54:1-35.
• Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30:1856-1883.
• Ito Y, Onoda N, Okamoto T. The revised clinical practice guidelines on the management of thyroid tumors by the Japan Associations of Endocrine Surgeons: Core questions and recommendations for treatments of thyroid cancer. Endocr J 2020;67:669-717.
• Borzooei, S., Briganti, G., Golparian, M., Lechien, J. R., & Tarokhian, A. (2024). Machine learning for risk stratification of thyroid cancer patients: a 15-year cohort study. European Archives of Oto-Rhino-Laryngology, 281(4), 2095-2104..
• Setiawan KE. Predicting recurrence in differentiated thyroid cancer: a comparative analysis of various machine learning models including ensemble methods with chi-squared feature selection. Commun Math Biol Neurosci 2024;55: 1-29.